Literature DB >> 17944588

[DOPPS estimate of patient life years attributable to modifiable hemodialysis practices in Spain].

L Piera1, J M Cruz, J L Braga-Gresham, M A Eichleay, R L Pisoni, F K Port.   

Abstract

The increased mortality risk in hemodialysis (HD) patients unable to meet six targets in different areas of HD practice has been reported previously. Using a prevalent cross-sectional sample of Spanish HD patients (n = 613) from the second stage of the Dialysis Outcomes and Practice Patterns Study to determine the percentage with low dialysis dose, hyperphosphatemia, hypercalcemia, hypoalbuminemia, anemia, and catheter use and based on the mortality hazard ratios and the total HD population in Spain, according to the Spanish Society of Nephrology Report, we estimated the number of patient life years that could potentially be gained in our country. These characteristics of HD practice were selected because each is modifiable through changes in practice, each is associated with mortality, and each has a large number of patients outside the target guidelines. The targets that define "within guidelines" are as follows: dialysis dose (single pool Kt/V >1.2), anemia (hemoglobin >110 g/L), albumin after standardization (>40 g/L), serum phosphorus (1.1-1.5 mmol/L), serum calcium (2.1-2.4 mmol/L), and facility catheter use (<10%). Cox proportional hazards regression models were used to calculate the relative risk of mortality for all patients outside each guideline. In all models, calcium values were adjusted for low serum albumin. A separate Cox survival model adjusted for all six HD practices simultaneously to account for correlation that may exist between some facility practices. All models were adjusted for age, sex, race, time on ESRD, and 14 summary comorbid conditions. Patient years attributable to each of the six practice patterns were estimated and are reported here as the potential patient years gained. Comparison of the estimates by individual guideline shows that, in Spain, increasing patient albumin above 40 g/L in all patients would lead to an estimated gain of 9,269 patient years (a 7.9% increase). Additionally, if all facilities could decrease catheter use to less than 10%, 2,842 patient years could be gained (a 2.4% increase). Though it may be an unrealistic goal, if all Spanish patients currently outside the guidelines achieved all six target levels, an estimated 17,300 life years could be gained over the next five years (a 15% increase). A more achievable goal of bringing 50% of patients who are currently outside targets within targets would result in 9,266 life years gained. In conclusion, this analysis suggests large opportunities to improve HD patient care in Spain.

Entities:  

Mesh:

Year:  2007        PMID: 17944588

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  3 in total

1.  Achievement of guideline targets in elderly patients on hemodialysis: a multicenter study.

Authors:  Nada Dimković; Ljubica Djukanović; Jelena Marinković; Živka Djurić; Violeta Knežević; Tatjana Lazarević; Stanimir Ljubenović; Rodoljub Marković; Violeta Rabrenović
Journal:  Int Urol Nephrol       Date:  2015-07-30       Impact factor: 2.370

2.  Greater fluid overload and lower interdialytic weight gain are independently associated with mortality in a large international hemodialysis population.

Authors:  Manfred Hecking; Ulrich Moissl; Bernd Genser; Hugh Rayner; Indranil Dasgupta; Stefano Stuard; Andrea Stopper; Charles Chazot; Franklin W Maddux; Bernard Canaud; Friedrich K Port; Carmine Zoccali; Peter Wabel
Journal:  Nephrol Dial Transplant       Date:  2018-10-01       Impact factor: 5.992

3.  Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study.

Authors:  Christian Combe; Johannes Mann; David Goldsmith; Frank Dellanna; Philippe Zaoui; Gérard London; Kris Denhaerynck; Andriy Krendyukov; Ivo Abraham; Karen MacDonald
Journal:  BMC Nephrol       Date:  2019-03-05       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.